An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA).
- Mechanism
- Curator reviewed
Arbekacin irreversibly binds bacterial 30S and 16S ribosomal subunits inhibiting protein synthesis. Arbekacin binds to 4 nucleotides of the 16S subunit and 1 amino acid of protein S12 to interfere with the decoding site around nucleotide 1400 in the 16S subunit. Interference with the decoding site interferes with its interaction with the wobble base of tRNA. This hindered interaction causes mRNA to be misread and the incorrect amino acids are inserted into protein. These error filled proteins are not able to function or may even be toxic.
- Primary indication
- Arbekacin is used for the short term treatment of multi-resistant bacterial infections, such as methicillin-resistant Staphylococcus aureus (MRSA).Curator reviewed
- Formula / weight
- C22H44N6O10 · 552.619 g/mol (avg)
- Also known as
- Haberacin
- Code names
- 1665-RB · AHB-DBK · HABA-Dibekacin · HABA-DKB · HBK · ME-1100
Resolves to
MKKYBZZTJQGVCD-XTCKQBCOSA-NSMILESNCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Arbekacin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account